New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance
30.9.2020 09:00:00 EEST | Business Wire | Press release
Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/
“Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of The Forrester WaveTM: Enterprise Data Fabric, Q2 2020. The report also states, “Denodo is known for data virtualization, and over the years it has also evolved into a data fabric vendor. Denodo’s data fabric solution integrates key data management components, including data integration, data ingestion, data transformation, data governance and security, to support new and emerging use cases including customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI/ML capabilities, as well as automation, continue to enhance its capabilities across data fabric components.”
Through data virtualization, the Denodo Platform offers enterprise-grade data integration, management, and delivery that rivals legacy data integration techniques. The new version of the Denodo Platform advances agile data integration and governed data management, extending Denodo’s reach into advanced hybrid and multicloud architectures and new data science use cases.
“Denodo 8.0 packs key capabilities that are essential for our Decision Support Initiative,” said Dan Young, chief data architect and manager at Indiana University, Bloomington. “Our mission is to provide timely, relevant, and accurate data for better decision making to our executives and faculty. The Denodo Platform has been a key technology in our logical data fabric architecture, integrating student and enrollment, personnel, and financial data, and delivering the unified information to our Academics Metrics (AM) 360 dashboards. With it, decision makers at Indiana University have been able to successfully measure, compare, and analyze trends regarding the health of their responsibility centers.”
Key functionalities of Denodo Platform 8.0 include:
- Hybrid cloud/multicloud integration: Denodo Platform 8.0 enables organizations to accelerate data integration across different locations while lowering operational costs and leveraging platform-as-a-service (PaaS)-style infrastructure automation and autoscaling support.
- Machine learning/data science automation: An ML-aided data catalog helps data scientists discover and prepare data for building complex data models and aids in supporting advanced analytics. With the integrated Apache Zeppelin Notebook, they can construct narratives combining queries with code, text, and graphics, and share it with fellow data scientists.
- API/microservices enhancements: New support for execution of GraphQL on top of logical data models promotes no-code approach to the use of REST APIs and accelerates the adoption of advanced microservices architectures.
- Hyper performance: Denodo Platform 8.0 maximizes query delegation and boosts performance to sub-second responses with AI-powered recommendations, advanced caching, and smart query acceleration for frequent, expensive queries.
- Unified Web-based UI with Single Sign-On: Newly introduced interface unifies all design and runtime tools with single sign-on support facilitating rapid design, development, deployment, and management processes.
“Denodo 8.0 is the result of years of continuous innovation to support our customers’ enterprise data management journeys,” said Alberto Pan, executive vice president and chief technology officer at Denodo. “Our customers have been pioneers in their respective industries, leveraging the Denodo Platform as the enterprise logical data fabric for advanced analytics, cloud modernization, data science, and data services. We responded to our customers’ requests by providing the most advanced data platform in the industry with PaaS-style infrastructure management, machine learning data catalog, GraphQL support, smart query acceleration, and an easy-to-use unified user interface.”
Recently, Denodo was named a Leader in the 2020 Gartner Magic Quadrant for Data Integration Tools.
Please Tweet: News: @denodo announces new Denodo Platform 8.0. Latest version supports advanced #DataVirtualization #DataFabric #HybridCloud #Multicloud #ML #AI #Microservices capabilities.
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, and cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005427/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom